Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies.

Por Uchuya, M, Graus, F, Vega, F, Reñé, R, Delattre, J Y
Publicado em 1996

O8.04 TEMOZOLOMIDE AFTER RADIOTHERAPY IN RECURRENT “LOW-GRADE” DIFFUSE BRAINSTEM GLIOMA IN ADULTS

Por Reyes-Botero, G., Laigle-Donadey, F., Mokhtari, K., Martin-Duverneuil, N., Delattre, J.Y.
Publicado em 2014

Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations.

Por Bardot, V., Dutrillaux, A. M., Delattre, J. Y., Vega, F., Poisson, M., Dutrillaux, B., Luccioni, C.
Publicado em 1994

T cell response to Hu-D peptides in patients with anti-Hu syndrome

Por Rousseau, A., Benyahia, B., Dalmau, J., Connan, F., Guillet, J.-G., Delattre, J.-Y., Choppin, J.
Publicado em 2005

Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo–associated paraneoplastic cerebellar degeneration

Por Rojas-Marcos, Iñigo, Picard, Geraldine, Chinchón, David, Gelpi, Ellen, Psimaras, Dimitri, Giometto, Bruno, Delattre, J.Y., Honnorat, J., Graus, F.
Publicado em 2012

Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice

Por Leuraud, P, Taillandier, L, Aguirre-Cruz, L, Medioni, J, Crinière, E, Marie, Y, Dutrillaux, A M, Kujas, M, Duprez, A, Delattre, J-Y, Poupon, M-F, Sanson, M
Publicado em 2003

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics

Por Mazzocco, P, Barthélémy, C, Kaloshi, G, Lavielle, M, Ricard, D, Idbaih, A, Psimaras, D, Renard, M‐A, Alentorn, A, Honnorat, J, Delattre, J‐Y, Ducray, F, Ribba, B
Publicado no CPT Pharmacometrics Syst Pharmacol (2015)

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations

Por Labussière, M, Di Stefano, A L, Gleize, V, Boisselier, B, Giry, M, Mangesius, S, Bruno, A, Paterra, R, Marie, Y, Rahimian, A, Finocchiaro, G, Houlston, R S, Hoang-Xuan, K, Idbaih, A, Delattre, J-Y, Mokhtari, K, Sanson, M
Publicado no Br J Cancer (2014)

Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222

Por Enciso-Mora, V, Hosking, F J, Di Stefano, A L, Zelenika, D, Shete, S, Broderick, P, Idbaih, A, Delattre, J-Y, Hoang-Xuan, K, Marie, Y, Labussière, M, Alentorn, A, Ciccarino, P, Rossetto, M, Armstrong, G, Liu, Y, Gousias, K, Schramm, J, Lau, C, Hepworth, S J, Schoemaker, M, Strauch, K, Müller-Nurasyid, M, Schreiber, S, Franke, A, Moebus, S, Eisele, L, Swerdlow, A, Simon, M, Bondy, M, Lathrop, M, Sanson, M, Houlston, R S
Publicado em 2013